It was observed in pre-clinical and clinical populations that FcRn and activating FcγR expression show no change or increase, while inhibitory FcγRIIb expression in spleen decreases in correlation with losses in skeletal muscle and lean mass in cancer. This evidence concerns the gene FCGR2B and cancer.